NCT04160715

Brief Summary

This is a multicenter prospective registry of IPF patients in South Korea. The Seoul National University Bundang Hospital is the coordination center for the Korean IPF Registry built by a collaboration of the Korean Interstitial Lung Diseases (ILD) Study Group.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
7mo left

Started Jan 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Jan 2016Dec 2026

Study Start

First participant enrolled

January 1, 2016

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

October 30, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 13, 2019

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

November 13, 2019

Status Verified

November 1, 2019

Enrollment Period

9 years

First QC Date

October 30, 2019

Last Update Submit

November 8, 2019

Conditions

Idiopathic Pulmonary Fibrosis

Outcome Measures

Primary Outcomes (1)

  • survival of IPF

    lung function change (FVC, DLCO)

    through study completion, an average of 1 year

Secondary Outcomes (3)

  • survival

    through study completion, an average of 1 year

  • acute exacerbation

    through study completion, an average of 1 year

  • incidence of comorbidity

    through study completion, an average of 1 year

Eligibility Criteria

Age30 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients with IPF

You may qualify if:

  • IPF patients diagnosed by multidisciplinary discussion

You may not qualify if:

  • Other interstitial lung diseases except for IPF
  • connective tissue disease-related ILD
  • exposure-related ILD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea

RECRUITING

Related Publications (1)

  • Moon SW, Kim SY, Chung MP, Yoo H, Jeong SH, Kim DS, Song JW, Lee HL, Choi SM, Kim YW, Kim YH, Park CS, Park SW, Park JS, Jegal Y, Lee J, Uh ST, Kim TH, Lee JH, Kim YH, Shin B, Lee HK, Yang SH, Lee H, Kim SH, Lee EJ, Choi HS, Shin H, Park YB, Shin JW, Park MS. Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study. Ann Am Thorac Soc. 2021 May;18(5):780-787. doi: 10.1513/AnnalsATS.202005-451OC.

    PMID: 33270528DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

serum, protein, DNA

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Study Officials

  • Man Pyo Chung, MD

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jong Sun Park, MD

CONTACT

jspark.im@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

October 30, 2019

First Posted

November 13, 2019

Study Start

January 1, 2016

Primary Completion

January 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

November 13, 2019

Record last verified: 2019-11

Locations

KR(1)